CORTLANDT MANOR, N.Y., Sept. 13, 2011 /PRNewswire/ — Polymedco,
Inc. is pleased to announce its exclusive agreement with Cardinal
Health, Inc., for distribution of its market leading automated FIT
product, a fecal occult blood analyzer that can help increase
patient compliance rates and aid in the early detection of
colorectal cancer. The agreement includes distribution of the
OC-Auto Micro 80; automated FIT analyzer; and OC-Sensor Diana, a
high throughput automated FIT analyzer, to the acute care market.
The Polymedco tests can help increase patient compliance rates,
because, unlike Guaiac tests, they require a single stool sample,
have no dietary or medicinal restrictions, and have a completely
closed sampling device. With this methodology, patient
compliance has been shown to as much as triple over prior testing
methods.
“We are extremely pleased to be working with a distributor of
the magnitude of Cardinal Health,” said Drew Cervasio, president of
Polymedco. “Polymedco is excited to offer a test with such
lifesaving capability and looking forward to delivering this
product to as many hospitals as possible and saving as many more
lives with the help of the Cardinal Health organization.”
Colorectal cancer is the third-leading cause of cancer death in
America, causing 50,000 deaths each year. Yet when detected early,
colorectal cancer is highly treatable, and patients with
precancerous polyps or early stage cancers often do not have to
follow-up with repeated surgeries and costly radiation and
chemotherapy. Annual screening for colorectal cancer, which
is facilitated by the OC-FIT line of products, is to saving lives
and containing healthcare costs.
“Cardinal Health is committed to supporting solutions which
drive cost-effectiveness and improve quality outcomes,” said Chris
Kerski, senior vice president and general manager of scientific
products at Cardinal Health. “We’re pleased with our partnership
with Polymedc
‘/>”/>